子宫乳腺肌肉瘤中的微RNA:从分子机制到临床应用
Areti Kourti1, Ioannis Kalogiannidis2, Kali Makedou3
1Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece.
International journal of molecular sciences
|November 27, 2025
概括
微RNAs (miRNAs) 是子宫乳腺髓瘤 (uLMS) 发展的关键参与者,影响其侵略性. 这些分子有潜力作为诊断和预后的生物标志物,以及作为LMS的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 子宫乳腺肌肉瘤 (uLMS) 是一种具有不良预后的侵袭性子宫光滑肌癌.
- 在手术前进行诊断是具有挑战性的,因为良性瘤和缺乏生物标志物的重叠特征.
- 微RNAs (miRNAs) 越来越多地被认为是癌症生物学中的角色.
研究的目的:
- 审查目前关于miRNAs在子宫乳腺肌肉瘤 (uLMS) 生物学和临床应用中的证据.
- 确定失调的miRNA,它们的向通路,以及它们作为LUMS的诊断和治疗工具的潜力.
主要方法:
- 在ULMS中对miRNA的分子和转化研究的文献综述.
- 分析miRNA表达特征,向途径和临床相关性.
主要成果:
- uLMS表现出一个独特的miRNA配置文件,具有下调的瘤抑制miRNA (例如,miR-29,miR-200) 和上调的瘤性miRNA (例如,miR-21,miR-183集群).
- 这些miRNAs调节PI3K/AKT/mTOR和上皮细胞-介质细胞过渡 (EMT) 等途径,有助于ULMS的发病.
- 循环和组织miRNAs显示潜在的最小侵入性生物标志物用于LMS诊断,预后和治疗指导.
结论:
- miRNAs 是 uLMS 病变的关键调节者.
- miRNAs在LMS中具有重要的精确诊断,预后和向治疗潜力.
- 对于基于miRNA的策略的临床转化,需要进一步的验证研究和改进的交付系统.
相关概念视频
MicroRNAs
3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs
23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K


